Kristin M Beima-Sofie1, Abigail W Bigham, Jairam R Lingappa, Dalton Wamalwa, Romel D Mackelprang, Michael J Bamshad, Elizabeth Maleche-Obimbo, Barbra A Richardson, Grace C John-Stewart. 1. aInstitute for Public Health Genetics bDepartment of Epidemiology cDepartment of Medicine dDepartment of Biostatistics eDepartment of Global Health fDepartment of Pediatrics gDepartment of Genome Sciences, University of Washington, Seattle, Washington hDepartment of Anthropology, University of Michigan, Ann Arbor, Michigan iVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA jDepartment of Paediatrics, University of Nairobi, Nairobi, Kenya.
Abstract
OBJECTIVE: We evaluated the association of single nucleotide polymorphisms (SNPs) in TLRs with infant HIV-1 acquisition and viral control. DESIGN: Infant HIV-1 outcomes were assessed in a Kenyan perinatal HIV-1 cohort. METHODS: Infants were genotyped for six candidate and 118 haplotype-tagging polymorphisms in TLRs 2, 3, 4, 7, 8, and 9, MYD88 and TIRAP. Cox proportional hazards and linear regression were performed to assess associations with time to HIV-1 acquisition, time to infant mortality, and peak viral load. RESULTS: Among 368 infants, 56 (15%) acquired HIV-1 by month 1 and 17 (4.6%) between 1 and 12 months. Infants with the TLR9 1635A (rs352140) variant were more likely to acquire HIV-1 by 1 month [hazard ratio = 1.81, 95% confidence interval (CI) = 1.05-3.14, P = 0.033] and by 12 months (hazard ratio = 1.62, CI = 1.01-2.60, P = 0.044) in dominant models adjusted for maternal plasma HIV-1 RNA level and genetic ancestry. Among 56 infants infected at 1 month of age or less, at least one copy of the TLR9 1635A allele was associated with a 0.58 log₁₀ copies/ml lower peak viral load (P = 0.002). Female infants with at least one copy of the TLR8 1G (rs3764880) variant had a 0.78 log₁₀ copies/ml higher peak viral load (P = 0.0009) and having at least one copy of the C allele for a haplotype tagging TLR7 variant (rs1634319) was associated with a 0.80 log₁₀ copies/ml higher peak viral load in female infants (P = 0.0003). CONCLUSION: In this African perinatal cohort, we found several TLR polymorphisms associated with HIV-1 acquisition and progression. Defining mechanisms for these TLR associations may inform HIV-1 prevention strategies that leverage innate responses.
OBJECTIVE: We evaluated the association of single nucleotide polymorphisms (SNPs) in TLRs with infantHIV-1 acquisition and viral control. DESIGN:InfantHIV-1 outcomes were assessed in a Kenyan perinatal HIV-1 cohort. METHODS:Infants were genotyped for six candidate and 118 haplotype-tagging polymorphisms in TLRs 2, 3, 4, 7, 8, and 9, MYD88 and TIRAP. Cox proportional hazards and linear regression were performed to assess associations with time to HIV-1 acquisition, time to infant mortality, and peak viral load. RESULTS: Among 368 infants, 56 (15%) acquired HIV-1 by month 1 and 17 (4.6%) between 1 and 12 months. Infants with the TLR9 1635A (rs352140) variant were more likely to acquire HIV-1 by 1 month [hazard ratio = 1.81, 95% confidence interval (CI) = 1.05-3.14, P = 0.033] and by 12 months (hazard ratio = 1.62, CI = 1.01-2.60, P = 0.044) in dominant models adjusted for maternal plasma HIV-1 RNA level and genetic ancestry. Among 56 infants infected at 1 month of age or less, at least one copy of the TLR9 1635A allele was associated with a 0.58 log₁₀ copies/ml lower peak viral load (P = 0.002). Female infants with at least one copy of the TLR8 1G (rs3764880) variant had a 0.78 log₁₀ copies/ml higher peak viral load (P = 0.0009) and having at least one copy of the C allele for a haplotype tagging TLR7 variant (rs1634319) was associated with a 0.80 log₁₀ copies/ml higher peak viral load in female infants (P = 0.0003). CONCLUSION: In this African perinatal cohort, we found several TLR polymorphisms associated with HIV-1 acquisition and progression. Defining mechanisms for these TLR associations may inform HIV-1 prevention strategies that leverage innate responses.
Authors: Natalia Soriano-Sarabia; Alejandro Vallejo; Reposo Ramírez-Lorca; María del Mar Rodríguez; Ana Salinas; Ildefonso Pulido; María E Sáez; Manuel Leal Journal: J Acquir Immune Defic Syndr Date: 2008-10-01 Impact factor: 3.731
Authors: D-Y Oh; S Taube; O Hamouda; C Kücherer; G Poggensee; H Jessen; J K Eckert; K Neumann; A Storek; M Pouliot; P Borgeat; N Oh; E Schreier; A Pruss; K Hattermann; R R Schumann Journal: J Infect Dis Date: 2008-09-01 Impact factor: 5.226
Authors: Djin-Ye Oh; Konstantin Baumann; Osamah Hamouda; Jana K Eckert; Konrad Neumann; Claudia Kücherer; Barbara Bartmeyer; Gabriele Poggensee; Nari Oh; Axel Pruss; Heiko Jessen; Ralf R Schumann Journal: AIDS Date: 2009-01-28 Impact factor: 4.177
Authors: Romel D Mackelprang; Abigail W Bigham; Connie Celum; Guy de Bruyn; Kristin Beima-Sofie; Grace John-Stewart; Allan Ronald; Nelly R Mugo; Kati J Buckingham; Michael J Bamshad; James I Mullins; M Juliana McElrath; Jairam R Lingappa Journal: J Infect Dis Date: 2013-12-10 Impact factor: 5.226
Authors: Daniel Menendez; Joyce Snipe; Jacqui Marzec; Cynthia L Innes; Fernando P Polack; Mauricio T Caballero; Shepherd H Schurman; Steven R Kleeberger; Michael A Resnick Journal: J Clin Invest Date: 2019-11-01 Impact factor: 14.808
Authors: B Willie; N B Hall; C M Stein; R J Jurevic; A Weinberg; R K Mehlotra; P A Zimmerman Journal: Genes Immun Date: 2014-09-25 Impact factor: 2.676
Authors: Elif Colak; Alasdair Leslie; Kieran Zausmer; Elham Khatamzas; Andriy V Kubarenko; Tica Pichulik; Sascha N Klimosch; Alice Mayer; Owen Siggs; Andreas Hector; Roman Fischer; Benedikt Klesser; Anna Rautanen; Martin Frank; Adrian V S Hill; Bénédicte Manoury; Bruce Beutler; Dominik Hartl; Alison Simmons; Alexander N R Weber Journal: J Immunol Date: 2014-05-09 Impact factor: 5.422